SCRT in TNT With or Without Chlorophyllin

Korábbi kezelés

• Recurrent rectal cancer or previous pelvic radiotherapy
• Patients with a history of venous thrombotic episodes such as deep venous thrombosis, and pulmonary embolism occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, patients who are anticoagulated for a trial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
• Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.

Más betegség

• Signet or mucinous histology cancer of rectum
• Primary unresectable rectal cancer.
• Patients with a history of any arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), MI, TIA, or CVA.
• Ulcerative colitis or any other histologically confirmed inflammatory bowel disease.

Laborértékek

• Creatinine level greater than 1.5 times the upper limit of normal.

Egyéb

• Patients who are unable to undergo an MRI.
• Poor reliability for follow up.
• Ineligible as per eligibility criteria

• Age > 18 years.
• Histologically confirmed diagnosis of adenocarcinoma of the rectum.
• Clinical Stage II/III (T2-3, 4b: adherent to prostate, SV or post vagina but not grossly invading, N0-2) based on MRI.
• Non-circumferential tumours with craniocaudal length <7 cm
• The tumours of the lower rectum, or starting up to 7 cm from the anal verge.
• No evidence of distant metastases on CT Chest and Abdomen.
• No prior pelvic radiation therapy
• No prior chemotherapy or surgery for rectal cancer
• Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
• Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.
• Eligible to receive one of the options of standard neoadjuvant chemotherapy as determined by the medical oncologist team.
  • Absolute neutrophil count (ANC) > 1.5 cells/mm3, hemoglobin (HGB) > 8.0 gm/dl, platelet (PLT) > 150,000/mm3.
  • Total bilirubin ≤ 1.5 x ULN (except in patients with Gilbert's Syndrome who must have total bilirubin ≤ 3.0 x ULN), aspartate aminotransferase (AST) ≤ 3 x ULN, alanine transaminase (ALT) ≤ 3 x ULN.